


This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claim 1 (currently amended) Compound represented by the formula:




or a pharmaceutically acceptable salt, ~~prodrug or ester~~ thereof, wherein t represents 0, 1 or 2;

R¹ represents hydrogen, alkyl of 1-5 carbon atoms, alkenyl of 2-5 carbon atoms, alkynyl of 2-5 carbon atoms, hydroxyalkyl of 1-3 carbon atoms, alkoxyalkyl of 1-3 alkyl and 1-3 alkoxy carbon atoms, cyanoalkyl of 1-3 alkyl carbon atoms, -CH₂CONH₂, -CH₂CH₂CONH₂, -CH₂S(O)₂NH₂, -CH₂SCH₃, -CH₂S(O)CH₃ or -CH₂S(O)₂CH₃ radicals;


R² represents radicals of alkyl of 1-5 carbon atoms, aralkyl of 1-3 alkyl carbon atoms, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthioalkyl of 1-3 alkyl carbon atoms or cycloalkylalkyl of 1-3 alkyl carbon atoms and 3-6 ring member carbon atoms;

R³ represents radicals of alkyl radical of 1-5 carbon atoms, cycloalkyl of 5-8 ring members or cycloalkylmethyl radical of 3-6 ring members;




R⁴ represents benzo fused 5 to 6 ring member heteroaryl or benzo fused 5 to 6 ring member heterocyclo radicals, or a radical of the formula



wherein A and B each independently represent O, S, SO or SO_2 ; R^6 represents deuterium, alkyl of 1-5 carbon atoms, fluoro or chloro radicals; R^7 represents hydrogen, deuterium, methyl, fluoro or chloro radicals; or a radical of the formula



wherein Z represents O, S or NH; and R^9 represents a radical of formula



wherein Y represents O, S or NH; X represents a bond, O or NR²¹;

R²⁰ represents hydrogen, alkyl of 1 to 5 carbon atoms, alkenyl of 2 to 5 carbon atoms, alkynyl of 2 to 5 carbon atoms, aralkyl of 1 to 5 alkyl carbon atoms, heteroaralkyl of 5 to 6 ring members and 1 to 5 alkyl carbon atoms, heterocycloalkyl of 5 to 6 ring members and 1 to 5 alkyl carbon atoms, aminoalkyl of 2 to 5 carbon atoms, N-mono-substituted or N, N-disubstituted aminoalkyl of 2 to 5 alkyl carbon atoms wherein said substituents are radicals of alkyl of 1 to 3 carbon atoms, aralkyl of 1 to 3 alkyl carbon atoms radicals, carboxyalkyl of 1 to 5 carbon atoms, alkoxy carbonylalkyl of 1 to 5 alkyl carbon atoms, cyanoalkyl of 1 to 5 carbon atoms or hydroxyalkyl of 2 to 5 carbon atoms;

R²¹ represents hydrogen radical or alkyl radical of 1 to 3 carbon atoms; or the radical of formula -NR²⁰R²¹ represents a 5 to 6 ring member heterocyclo radical; and

R²² represents alkyl radical of 1 to 3 carbon atoms or R²⁰R²¹N-alkyl radical of 1 to 3 alkyl carbon atoms; and

R⁵ represents an alkyl radical of 1-5 carbon atoms, alkenyl radical of 2-5 carbon atoms, alkynyl radical of 2-5 carbon atoms or aryl substituted alkyl radical of 1-5 carbon atoms.

Claims 2-11 (canceled)


Claim 12 (currently amended) Compound of claim 1, or a pharmaceutically acceptable salt, ~~prodrug or ester~~ thereof, wherein t represents 1 or 2;

R¹ represents hydrogen radical, alkyl radical of 1-3 carbon atoms, alkenyl radical of 2-3 carbon atoms, alkynyl radical of 2-3 carbon atoms radicals or cyanomethyl;


R² represents radicals of alkyl of 3-5 carbon atoms, arylmethyl, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthiomethyl or cyloalkylmethyl of 5-6 ring member carbon atoms radicals;

R³ represents alkyl of 1-5 carbon atoms, cyloalkylmethyl of 3-6 ring members, cyclohexyl or cycloheptyl radicals;




R⁴ represents 2-amino-benzothiazol-5-yl, 2-amino-benzothiazol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzoxazol-5-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl or 1,4-benzodioxan-6-yl radicals; or a radical of the formula



wherein A and B each represent O; R⁶ represents deuterium, methyl, ethyl, propyl, isopropyl or fluoro radicals; and R⁷ represents hydrogen, deuterium, methyl or fluoro radicals; or a radical of the formula



wherein Z represents O, S or NH; and R⁹ represents a radical of formula



wherein Y represents O, S or NH; X represents a bond, O or NR²¹;

R²⁰ represent hydrogen, alkyl of 1 to 5 carbon atoms, phenylalkyl of 1 to 3 alkyl carbon atoms, heterocycloalkyl of 5 to 6 ring members and 1 to 3 alkyl carbon atoms, or N-mono-substituted or N,N-disubstituted aminoalkyl of 2 to 3 alkyl carbon atoms wherein said substituents are alkyl radicals of 1 to 3 carbon atoms; and

R²¹ represents hydrogen or methyl radicals; or the radical of formula -NR²⁰R²¹ represents pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, morpholinyl or thiomorpholinyl radicals; and

R²² represents alkyl radical of 1 to 3 carbon atoms; and

R⁵ represents an alkyl radical of 1-5 carbon atoms, alkenyl radical of 3-4 carbon atoms, alkynyl radical of 3-4 carbon atoms or aryl substituted alkyl radical of 1-4 carbon atoms.


Claim 13 (currently amended) Compound of claim 12, or a pharmaceutically acceptable salt, ~~prodrug or ester~~ thereof, wherein

R¹ represents hydrogen, methyl, ethyl or cyanomethyl radicals;




R² represents isobutyl, n-butyl, CH₃SCH₂CH₂-, phenylthiomethyl, (2-naphthylthio)methyl, benzyl, 4-methoxyphenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals;

R³ represents propyl, isoamyl, isobutyl, butyl, cyclohexyl, cycloheptyl, cylopentylmethyl or cyclohexylmethyl radicals; and

R⁴ represents benzothiazol-5-yl, benzothiazol-6-yl, benzoxazol-5-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-1,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-1,3-benzodioxol-5-yl, 2,2-difluoro-1,3-benzodioxol-5-yl or 1,4-benzodioxan-6-yl radicals; or a radical of the formula



wherein Z represents O, S or NH; and R⁹ represents a radical of formula



wherein Y represents O, S or NH; X represents a bond, O or NR²¹;

R²⁰ represents hydrogen, methyl, ethyl, propyl, isopropyl, isobutyl, benzyl, 2-(1-pyrrolidinyl)ethyl, 2-(1-piperidinyl)ethyl, 2-(1-piperazinyl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 2-(1-morpholinyl)ethyl, 2-(1-thiamorpholinyl)ethyl or 2-(N,N-dimethylamino)ethyl radicals;

R²¹ represents a hydrogen radical; and

R²² represents methyl radical; and

R⁵ represents an alkyl radical of 1-5 carbon atoms or phenyl substituted alkyl radical of 2-4 carbon atoms.

Claim 14 (currently amended) Compound of claim 13 or a pharmaceutically acceptable salt, ~~prodrug or ester~~ thereof, wherein

R¹ represents methyl or ethyl radicals;

R² represents benzyl, 4-fluorophenylmethyl or cyclo hexylmethyl radicals;

R⁴ represents benzothiazol-5-yl, benzothiazol-6-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-1-,3-benzodioxol-5-yl, 2,2-dimethyl-1,3 benzodioxol-5-yl, 2,2-dideutero-1,3-benzodioxol-5-yl, 2,2-difluro-1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2-(methoxycarbonylamino) benzothiazol-6-yl or 2-(methoxycarbonylamino) benzimidazol-5-yl radicals; and

R⁵ represents methyl, ethyl, propyl, isopropyl or 2-phenylethyl radicals.

Claim 15 (currently amended) Composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Claim 16 (currently amended) Method of inhibiting a retroviral protease comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Claim 17 (currently amended) Method of treating a retroviral infection comprising administering an effective amount of a composition of claim 15 or a pharmaceutically acceptable salt thereof.

Claim 18 (canceled)

Claim 19 (currently amended) Method of preventing replication of retrovirus in vitro comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Claim 20 (currently amended) Method of treating AIDS comprising administering an effective amount of a composition of claim 15 or a pharmaceutically acceptable salt thereof.